Abstract:The Ras proteins play an important role in cell growth, differentiation, proliferation and survival by regulating diverse cellular pathways. KRAS is the most frequently mutated class of Ras superfamily in all human cancers (21.6%), thus stimulating intensive efforts in developing effective approaches including new drugs to combat various KRAS-mutant-driven cancers. While accumulating evidence supports KRAS as an evolving cancer target, no effective anti-KRAS medications have yet been approved for clinical use to date. Here, we present a concise overview of advances with respect to indirect and direct strategies targeting aberrant KRAS signaling.

KRAS - an Evolving Cancer Target.